Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma

Virchows Archiv

Volumn 467, Issue 4, 2015, Pages 443-448

  Krpina, Kristian ^a   Babarović, Emina ^b   Jonjić, Nives ^b  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Lymphocytes; Non muscle invasive bladder cancer; Recurrence; Treatment; Tumor infiltrating

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR ASSOCIATED LEUKOCYTE; BLADDER TUMOR; CANCER GRADING; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; VERY ELDERLY;

CD3 ANTIGEN; CD8 ANTIGEN;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD8; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84944513973     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-015-1808-6     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62:10–29
2. Knowles MA (2008) Molecular pathogenesis of bladder cancer. Int J Clin Oncol 13:287–297
3. Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association (2009) Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese Urological Association. Int J Urol 16(3):279–86
4. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM, Sole GM (2010) Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl 92(6):519–24
5. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477
6. Lv S, Turlova E, Zhao S, Kang H, Han M, Sun HS (2014) Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis. Tumor Biol 35(2):1565–1574
7. Zachos I, Tzortzis V, Mitrakas L, Samarinas M, Karatzas A, Gravas S, Vandoros GP, Melekos MD, Papavassiliou AG (2014) Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG. Tumor Biol 35(5):4185–4189
8. Wieder T, Braumüller H, Kneilling M, Pichler B, Röcken M (2008) T cell-mediated help against tumors. Cell Cycle 7(19):2974–2977
9. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 7:10–16
10. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R (1993) Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 29A(1):69–75
11. Gakis G, Todenhöfer T, Renninger M, Schilling D, Sievert KD, Schwentner C, Stenzl A (2011) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 108(11):1800–1805
12. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S (2006) Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 55:734–743
13. Loskog A, Ninalga C, Paul-Wetterberg G, de laTorre M, Malmstrom PU, Totterman TH (2007) Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 177:353–358
14. Ebelt K, Babaryka G, Figel AM, Pohla H, Buchner A, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E (2008) Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 68:1–10
15. Adler AJ (2007) Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets 7:3–14
16. Leong PP, Mohammad RI, Ibrahim N, Abdalla NH, Davis WC, Scow HF (2006) Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 102(2):229–236
17. Unitt E, Rushbrook SM, Marshal A, Davies S, Gibbs P, Morris LS (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma, the role of T-regulatory cells. Hepatol 41(4):700–2
18. Lamagna C, Aurrand-Lions M, Imhof BA (2006) Dual role of macrophages in tumor growth and angiogenesis. Step of the angiogenesis cascade. J Leukoc Biol 80:705–713
19. Stout RD, Watkins SK, Suttles J (2009) Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol 86:1105–1109
20. Ayari C, Larue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y (2009) Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to Bacillus Calmette-Guerin immunotherapy. Eur Urol 55(6):1386–1396
21. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S (2004) Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 99:1667–74
22. Ishigami S, Natsugoe S, Tokuda K (2003) Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res 23:4079–83